News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epizyme Files for IPO of Up to $69 Million



4/19/2013 7:57:51 AM

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company recently entered into a collaboration agreement with Abbott Laboratories to develop a diagnostic to detect which patients would qualify for Epizyme's product candidates. The Cambridge, MA-based company, which was founded in 2007 and booked $45 million in collaboration revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol EPZM.

Read at Nasdaq
Read at Street Insider
Read at News Release


comments powered by Disqus
Epizyme
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES